Eli Lilly And Co (NYSE:LLY) SVP Daniel Skovronsky acquired 10,000 shares of the stock in a transaction that occurred on Thursday, June 14th. The shares were bought at an average price of $86.22 per share, for a total transaction of $862,200.00. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Eli Lilly And Co stock traded up $0.63 during midday trading on Thursday, reaching $86.35. The stock had a trading volume of 3,115,100 shares, compared to its average volume of 4,463,948. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $89.09. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.01 and a current ratio of 1.41. The firm has a market capitalization of $93.20 billion, a price-to-earnings ratio of 20.18, a P/E/G ratio of 1.45 and a beta of 0.29.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, April 24th. The company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.21. Eli Lilly And Co had a net margin of 4.82% and a return on equity of 35.37%. The firm had revenue of $5.70 billion during the quarter, compared to analyst estimates of $5.51 billion. During the same quarter last year, the business posted $0.98 EPS. The company’s revenue was up 9.0% on a year-over-year basis. equities analysts forecast that Eli Lilly And Co will post 5.15 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, June 8th. Investors of record on Thursday, May 17th were paid a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a yield of 2.61%. The ex-dividend date was Wednesday, May 16th. Eli Lilly And Co’s dividend payout ratio is 52.57%.
A number of institutional investors have recently bought and sold shares of LLY. Franklin Resources Inc. boosted its stake in Eli Lilly And Co by 14.1% in the 1st quarter. Franklin Resources Inc. now owns 32,541,775 shares of the company’s stock worth $2,517,762,000 after purchasing an additional 4,022,251 shares during the period. Schroder Investment Management Group boosted its stake in Eli Lilly And Co by 103.8% in the 1st quarter. Schroder Investment Management Group now owns 4,689,223 shares of the company’s stock worth $362,806,000 after purchasing an additional 2,388,548 shares during the period. Investec Asset Management LTD acquired a new position in Eli Lilly And Co in the 4th quarter worth approximately $163,570,000. BlackRock Inc. boosted its stake in Eli Lilly And Co by 3.0% in the 1st quarter. BlackRock Inc. now owns 65,780,446 shares of the company’s stock worth $5,089,436,000 after purchasing an additional 1,926,334 shares during the period. Finally, Amundi Pioneer Asset Management Inc. boosted its stake in Eli Lilly And Co by 110.9% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 1,832,626 shares of the company’s stock worth $154,783,000 after purchasing an additional 963,776 shares during the period. 76.09% of the stock is owned by hedge funds and other institutional investors.
LLY has been the topic of a number of research analyst reports. Jefferies Financial Group set a $90.00 price objective on shares of Eli Lilly And Co and gave the company a “buy” rating in a research note on Friday, April 13th. Credit Suisse Group set a $80.00 price objective on shares of Eli Lilly And Co and gave the company a “hold” rating in a research note on Sunday, April 22nd. Zacks Investment Research lowered shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Wednesday, May 23rd. JPMorgan Chase & Co. set a $105.00 price objective on shares of Eli Lilly And Co and gave the company a “buy” rating in a research note on Monday, February 26th. Finally, ValuEngine lowered shares of Eli Lilly And Co from a “hold” rating to a “sell” rating in a research note on Wednesday, May 2nd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the stock. Eli Lilly And Co has an average rating of “Buy” and a consensus target price of $93.89.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.